IntegraGen Announces Collaborative Agreement with Pfizer to Evaluate
IntegraGen’s Proprietary Hepatocellular Carcinoma Molecular Signature
EVRY, France -- April 3, 2014
Regulatory News :
IntegraGen (Paris:ALINT), a leading player in the development and marketing of
molecular diagnostic testing in oncology and autism, announced today that it
has entered into an agreement with Pfizer Inc. that provides Pfizer access to
evaluate the company’s proprietary molecular signature for hepatocellular
carcinoma. The 56-gene molecular signature covered by the agreement is
intended to predict the clinical prognosis of patients with hepatocellular
carcinoma and subcategorize patients into six separate classifications based
on the molecular characteristics of their liver tumors.
“We are pleased to have our molecular signature evaluated by one of the
world’s leading pharmaceutical companies,” said Dr. Bernard Courtieu,
IntegraGen’s Chief Executive Officer. “The use of our molecular signature may
help to identify specific patient populations who would benefit from Pfizer’s
experimental compounds, if approved by regulatory authorities. We are also
extremely appreciative of the research conducted by Professor Jessica
Zucman-Rossi, which led to the development of this molecular signature with
the continued support of the French League Against Cancer Program ‘Cartes
d’Identité des Tumeurs®’ (CIT).”
Terms of the agreement were not disclosed.
Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on
the development and commercialization of molecular diagnostic tests in the
fields of autism and oncology. IntegraGen’s mission is to translate molecular
research into clinical practice through the identification of novel genetic
biomarkers and the subsequent development of molecular diagnostic tests which
allow clinicians to better manage the clinical care of their patients.
IntegraGen is also a leader in delivering expert genomic service solutions to
academic researchers and life sciences companies as a result of its scientific
knowledge and technological expertise related to cutting edge genomic
platforms and bioinformatics.
For more information on IntegraGen visit www.integragen.com
ABOUT THE FRENCH LEAGUE AGAINST CANCER
The French League Against Cancer is an non-profit, non-governmental
organization that is an independent voluntary funder of research against
cancer. With nearly 700,000 members and 13,000 volunteers, the League is a
grassroots movement organized into a federation of 103 local committees.
Together, they fight in three complementary directions: search for cure,
prevent to protect, support for help. Today, the League is making the fight
against cancer a societal issue bringing together the largest possible number
of health actors but also economic, social or political actors in all
territories. Breaking taboos and fears, the League contributes to change the
image of cancer and those who are affected. The French League Against Cancer
finances and manages a national program of cancer genomics, called CIT “Cartes
d’Identité des Tumeurs®” (Tumors Identity Cards). This program
(http://cit.ligue-cancer.net) aims at characterizing multiple tumor types on a
pangenomic scale to progress toward personalized medicine.
For more information visit www.ligue-cancer.net or follow us at
www.facebook.com/laliguecontrelecancer or at twitter.com/laliguecancer
Laurence RIOT LAMOTTE
Tel.: +33 (0)1 60 91 09 00
FRENCH LEAGUE AGAINST CANCER
Elodie Audonnet, Tel: +33 (0) 1 53 55 25 31
Investor and Media relations
Tel.: +33 (0)1 44 71 94 94
Press spacebar to pause and continue. Press esc to stop.